THE TECHNOLOGY
MRG therapeutics are believed to represent a paradigm shift in regenerative medicine and patient care. It has long been recognised that a stem cells ability to self-renew and their capacity for differentiation offers significant potential for the generation and repair of tissues. However, there were four significant challenges.
Micregen’s intellectual property is being developed to deliver protected production processes that overcomes these challenges.
Whole stem cell therapies have shown significant benefit over many years, across a wide range of disease and illness. Research shows that despite the observed benefits of the whole cell-based treatments, the proportion of cells that engraft into damaged tissue (the expected mechanism of action) is dramatically lower than the number of whole stem cells introduced. In fact, many of the beneficial effects were discovered to come from the paracrine acting secretions of the introduced whole stem cells.
Whole stem cell therapies have shown significant benefit over many years, across a wide range of disease and illness. Research shows that despite the observed benefits of the whole cell-based treatments, the proportion of cells that engraft into damaged tissue (the expected mechanism of action) is dramatically lower than the number of whole stem cells introduced. In fact, many of the beneficial effects were discovered to come from the paracrine acting secretions of the introduced whole stem cells.
This short video demonstrates the potential for Micregen’s Secretomix to home into damage and release its repairing cargo. The video shows the paracine factors of MRG1061 labelled with a fluorescent dye penetrating a target cell. Location of the labelled extra-cellular vesicles was determined by taking optical slices through confocal microscopy. Optical slices were aligned to generate a 3-D image which show the nuclei in blue surrounded by the cytoplasm in brown. Bright speckles in the cytoplasm show the location of individual extracellular-vesicles.
This short video demonstrates the potential for Micregen’s Secretomix to home into damage and release its repairing cargo. The video shows the paracine factors of MRG1061 labelled with a fluorescent dye penetrating a target cell. Location of the labelled extra-cellular vesicles was determined by taking optical slices through confocal microscopy. Optical slices were aligned to generate a 3-D image which show the nuclei in blue surrounded by the cytoplasm in brown. Bright speckles in the cytoplasm show the location of individual extracellular-vesicles.
This short video demonstrates the potential for Micregen’s Secretomix to home into damage and release its repairing cargo. The video shows the paracine factors of MRG1061 labelled with a fluorescent dye penetrating a target cell. Location of the labelled extra-cellular vesicles was determined by taking optical slices through confocal microscopy. Optical slices were aligned to generate a 3-D image which show the nuclei in blue surrounded by the cytoplasm in brown. Bright speckles in the cytoplasm show the location of individual extracellular-vesicles.
Secretomix facilitate cell repair, reduce inflammation, reduce scarring, improve blood flow and generate a pro-regenerative microenvironment across a wide range of organs and tissue types. Micregen believe that their innovative approach has the potential to change the way that multiple critical and chronic problems are managed. Secretomix are cell-free biologics of stem cell origin.
Micregen’s Intellectual Property revolves around the development, optimisation, and manufacture of Micregen’s stem cell-derived, cell-free secretome therapeutics (“MRG Therapeutics”). These form the platform and are the basis for the development of therapeutics that accelerate regeneration and repair. The overarching goal and aim is to substantially improve patients’ health and wellbeing.
MRG Therapeutics
Micregen's therapeutics activate resident stem cells to repair damaged cells, reduce inflammation and scarring, improve blood flow and generate a pro-regenerative microenvironment across a wide range of organs.
Secretomix are a cell free approach, this reduces tumour risk or the inappropriate development of the wrong tissue type. These discoveries will enable Micregen to overcome significant barriers to translate stem cell technology into all areas of clinical medicine.
Micregen's therapeutics activate resident stem cells to repair damaged cells, reduce inflammation and scarring, improve blood flow and generate a pro-regenerative microenvironment across a wide range of organs.
Secretomix are a cell free approach, this reduces tumour risk or the inappropriate development of the wrong tissue type. These discoveries will enable Micregen to overcome significant barriers to translate stem cell technology into all areas of clinical medicine.
Furthermore, they harness the body's natural healing process and gain many of the clinical benefits whilst reducing the associated risks of conventional pharmaceuticals of overdose and contra-indication (major complications and even fatality if taken with certain other medicines) which is particularly relevant to an ageing population who take multiple prescriptions.
Since 2019 there has been an exponential growth in peer reviewed, published, scientific papers confirming Micregen’s approach, (600+ papers published in 2019 alone).
MRG1061
MRG1061 is Micregen’s first product which aims to target neonatal conditions. It is a multipotent, allogeneic, Amniotic Fluid Stem Cell derived, cell-free injectable and is designed to aid tissue regeneration.
The first clinical target is necrotising enterocolitis, an often-fatal condition in premature & new-born babies where portions of the bowel undergo wide-spread necrosis (tissue death).
MRG1061
MRG1061 is Micregen’s first product and aims to target neonatal conditions. It is a multipotent, immortalised, stem cell-derived, cell-free injectable, designed to aid tissue regeneration.
The first clinical target is necrotising enterocolitis, an often-fatal condition in premature & new-born babies where portions of the bowel undergo wide-spread necrosis (tissue death).
MRG1161
MRG1161 is Micregen’s second product. MRG1161 is a pluripotent, allogeneic, stem cell-derived cell-free injectable designed to alleviate problems associated with ageing.
The first clinical target is disuse associated muscle atrophy and frailty. It is recognised that even after short period of inactivity (a short hospital stay or a week ‘off your feet’) has a serious and very detrimental effect in the older population’s ability to remain active and resume everyday tasks. Studies have shown that a week of inactivity in the over 60’s can result in a loss of muscle mass of up to 60%.
Micregen believe that MRG1161 has the potential to provide an important partial solution to this problem, allowing people to lead healthier, more active lives (increasing health-span) thereby dramatically improving quality of life.
